A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan

Launched by BRISTOL-MYERS SQUIBB · Nov 22, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a medication called deucravacitinib, which is being studied to see how safe and effective it is for treating plaque psoriasis—a common skin condition that causes red, scaly patches. The trial is specifically for people in Japan who are starting treatment with this medication for the first time.

To participate, individuals need to have been diagnosed with plaque psoriasis and must be receiving deucravacitinib as approved by their healthcare provider. However, those who are using the medication for reasons not approved will not be eligible for the study. Participants can expect to be monitored for their health and any side effects while taking the medication. The study is currently recruiting participants of all ages and genders, aiming to gather important information about how well this treatment works in a real-world setting.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Psoriasis (PsO) participants who received Deucravacitinib for the first time of the approved indications at medical institutions in Japan will be enrolled in this PMS
• Exclusion Criteria:
• • Participants receiving Deucravacitinib for an off-label indication will be excluded from this PMS.